UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • UCB in Epilepsy and Rare Syndromes

     

    For three decades, we’ve been committed to people living with epilepsy and their families, surrounding the patient and caregiver through every step of their care journey – from diagnosis to treatment to support in helping them navigate those moments in their lives that matter most. Because we must find solutions for seizures that won’t stop, not only to preserve those moments, but to protect the minds and the lives of those living with epilepsy and rare syndromes.

    Driven by Patient Value

    At our core, we have a profound responsibility to elevate the healthcare ecosystem. It is a responsibility that extends to the very heart of our purpose – patients, and their families. Thirty years ago, we ushered in a new era of epilepsy therapies largely due to our scientific breakthrough, introducing a completely unique and novel mechanism of action in the treatment of epilepsy and, we continued to redefine the SV2A class of medicines to treat seizures.

    Commitment to People, Purpose and Science

    We will continue to reimage how we care for patients, leveraging today s expertise for a better tomorrow. We are doing so, in many instances, on our own as we look at potential solutions for rapid seizure termination, our work in Developmental and Epileptic Encephalopathies (DEEs), and our pursuits in gene modification. But we understand that with the complexity of the ecosystem, there are instances where we will need to partner with purpose. Therefore, we are also pursuing external research collaborations to validate new potential therapeutic targets. With so much experience behind us and so much potential ahead, we are more invested than ever in profoundly improving the lives of those living with or caring for those with epilepsy or a rare epilepsy syndrome.

     

    Resources

    VIP Sibling

    We partnered with the Lennox-Gastaut Syndrome (LGS) Foundation and Dravet Syndrome(DS) Foundation to compile the Siblings Voices Survey to assess how children adapt to growing up with siblings living with a rare form of epilepsy and created our VIP Sibling Project that includes resources to support siblings, parents, and caregivers of people living with a rare epilepsy syndrome.

    SUDEP

    We worked with more than 20 organizations committed to this community such as American Epilepsy Society, Danny Did Foundation, and the Epilepsy Foundation, and Child Neurology Foundation (CNF), to support the creation a toolkit of resources to raise awareness of potential causes of SUDEP.

    Digital Care Transformation 

    We continuously seek to innovate for the future creating our Digital Care Transformation incubator. Through this initiative, we support healthcare startups developing innovative solutions for epilepsy, such as NeuroHelp and Epihunter, using AI and wearable technology. We have also invested in detection and monitoring device companies like Neurava, Nextsense, Eysz, and Byteflies who are developing advanced technologies to improve seizure detection and monitoring, elevating the standard of care.